Type 2 diabetes; age 50 years or older and established CV disease or chronic renal failure OR age >60 years and risk factors for CV disease, HbA1c >7%Randomized to liraglutide or placebo both in addition to standard-of-care. Follow-up 3.5-5 years.Mean age 65 years.Exclusions: type 1 diabetes, use of GLP-1 agonist, DDP-4 inhibitors, pramlitinide, or rapid-acting insulin, history of MEN type 2 or medullary thyroid cancer and occurrence of an acute coronary or cerebrovascular event. Here, INS is linked to type 2 diabetes mellitus.